STAT1 and lymphoma: While pharmacological inhibitors chosen for targeting transcriptional regulatory factors, besides TARDP1 (XAV939) [43], targeted HDAC1 (abexinostat) [44], STAT1 (fludarabine) [45], NONO (auranofin) [46], DNMT1 (thioguanine) [47], and ETS1 (YK-4-279) [48], all resulted in decreased cell viability in the lymphoma cell lines in a concentration-dependent manner, in both lymphoma and LCL cells (see Figure S1).